IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
about
Targeted immune therapy of ovarian cancerA randomized trial of diet and physical activity in women treated for stage II-IV ovarian cancer: Rationale and design of the Lifestyle Intervention for Ovarian Cancer Enhanced Survival (LIVES): An NRG Oncology/Gynecologic Oncology Group (GOG-225) SInterleukin-6 Signaling Pathway and Its Role in Kidney Disease: An UpdateTherapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer.Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy.Neutrophils in the tumor microenvironment: trying to heal the wound that cannot heal.IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients.Myeloid-derived suppressor cells are involved in lysosomal acid lipase deficiency-induced endothelial cell dysfunctions.Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10.Multiple signal pathways in obesity-associated cancer.Minocycline suppresses interleukine-6, its receptor system and signaling pathways and impairs migration, invasion and adhesion capacity of ovarian cancer cells: in vitro and in vivo studies.An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor responseGastric cancer-associated enhancement of von Willebrand factor is regulated by vascular endothelial growth factor and related to disease severity.Sex differences in the relationship of IL-6 signaling to cancer cachexia progressionPlasma immune analytes in patients with epithelial ovarian cancer.Interleukin-6 as a therapeutic target in human ovarian cancerVasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2.Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways.Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring.Sprouty2 protein in prediction of post-treatment ascites in epithelial ovarian cancer treated with adjuvant carbotaxol chemotherapy.Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated PeritonitisTumor-Activated Mesenchymal Stromal Cells Promote Osteosarcoma Stemness and Migratory Potential via IL-6 Secretion.Profiling of cytokines in human epithelial ovarian cancer ascites.Shear-dependent attenuation of cellular ROS levels can suppress proinflammatory cytokine injury to human brain microvascular endothelial barrier properties.Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients.A Nanoparticle Based Sp17 Peptide Vaccine Exposes New Immuno-Dominant and Species Cross-reactive B Cell Epitopes.Formyl Peptide Receptor Activation Elicits Endothelial Cell Contraction and Vascular Leakage.CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signalingSyk/JNK/AP-1 signaling pathway mediates interleukin-6-promoted cell migration in oral squamous cell carcinomaThe immune system in the pathogenesis of ovarian cancer.A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model.Hitting a complex target: an update on interleukin-6 trans-signalling.IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6.Oncogene and non-oncogene addiction in inflammation-associated cancers.gp130: a promising drug target for cancer therapy.Lysophosphatidic acid signaling in ovarian cancer.The role and therapeutic targeting of IL-6 in rheumatoid arthritis.
P2860
Q28082828-53707BCB-92FD-4027-8280-4C4E5997DD4AQ30355266-B36F94E0-51F4-4014-B4E8-D70D947FD446Q33586501-8B6A5E5E-F46D-4757-93BF-10EC0A497771Q33678588-36E5BF49-82A1-4D77-B307-18886250C9A2Q33714950-1DC37F88-EB74-4AA4-A36A-F531F574FE5DQ33816141-1A04DB45-8024-475C-A1DF-CA20DB3D1FC2Q33889122-547DAE42-0D71-463B-89A2-87CDDFBF944EQ33914512-693F0AA6-3B94-4B25-A312-58C58384844DQ33992611-15CB8650-0615-4AC1-B3DC-D8355A5BB504Q34205626-020C1F2E-7244-45BF-8EBB-F69E4FFA2534Q34633750-3BE90CDB-E984-4980-B24B-BA3437DCCF4AQ34674172-086E5F6E-5E28-4FDA-BD8C-54FE0CC0500AQ34868121-91E67298-43CA-4411-8781-3AB4EFB5AB00Q35121586-5BCF841D-0FE1-41C4-B32F-001A1CE58460Q35214154-271F3D79-42D6-4F9E-9D3F-BD75CABA42F9Q35236090-93DD3C39-64F0-4A42-89E4-01D29D9275E4Q35239088-6E745BC3-5AD3-46C2-89F9-D7889CC4E637Q35695381-A0A6ED08-6BFD-4DB6-B32E-6E88A5D360BAQ35837949-E24F51F6-A28E-4449-8683-5243BB6E4CF2Q35905939-2A04835B-AB89-42BC-B1AC-EAD54FF17FF3Q35908928-63887921-34D9-4AA2-AC2B-C33DEE370DFAQ35964621-18CBCA97-A243-4EE7-B72A-F3AB30067D06Q36057153-106C1A6A-3901-430E-BD39-FD909DCA5572Q36092550-38DE7925-D8F5-4700-9ABA-DDAD1B9A78C7Q36194212-36A6C7DE-2CFD-466C-BC65-B6916998F3A1Q36206483-909DDCC7-50BB-4A99-ABE0-2C18DDE180EAQ36267412-22144809-03B0-4E6D-BD76-74248739A390Q36317366-D81698BE-1817-47B7-A476-1DCDF336A974Q36409524-47C24DBE-8A2C-496E-B524-32C38D815EFDQ37146198-95D5F08F-8F74-490E-B6F2-46FE8D7802C7Q37244183-6ED0359D-179B-454E-B2FD-B5FF427C02A2Q37535480-F56C19CA-92CE-44E2-8D11-4B751E24DB8CQ37613407-91CA8D59-648D-4686-9D59-2AEB7CC839FBQ37691064-CC09BDC0-D061-486D-8417-08FB468E14AAQ37983123-4242E193-68A2-403E-857E-9A5C8A3442D8Q38058509-E9F13DBD-B70B-4B48-904B-8D36F6155627Q38096415-4EB7D222-830D-405E-B87F-8B94DD913389Q38149939-5580E276-8D01-44C8-BAA8-D4652D3787B2Q38590952-F9A865A2-26B1-4C7D-98F0-FA8206CA4C75Q38685086-DF219E18-D84C-4121-B229-41B648ACA8A5
P2860
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
@en
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
@nl
type
label
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
@en
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
@nl
prefLabel
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
@en
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
@nl
P2093
P50
P1433
P1476
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer.
@en
P2093
Chi-Wen Lo
Jeng-Shou Chang
Lin-Hung Wei
Min-Wei Chen
Sheng-Mou Hsiao
Shiuan Wang
Tsung-Ching Lai
P304
P356
10.1158/0008-5472.CAN-10-1496
P407
P577
2010-12-01T00:00:00Z